Primary and Secondary End Points
anxiety, pain
SECONDARY
The primary endpoint was a pain reduction of 1.5 points on the VAS for patients included in the VR group in comparison with the MEOPA group. The secondary objectives were the number of lidocaine vials used; duration of exposure to MEOPA (not evaluated in the VR arm); tolerance of the VR session; anxiety level before and after the biopsy; sense of presence for the VR arm; level of residual pain and memory of pain after 1 month of follow-up; and assessment of patient, nurse, and physician satisfaction.